MINNEAPOLIS — A new initiative to reduce the use of opioids at the VA already is demonstrating some success at eight launch sites in Minnesota, where high-dose use of the painkillers has been reduced more than 50%.
TITUSVILLE, NJ — Food and Drug Administration approval of Topamax (topiramate) for migraine headaches prophylaxis has been extended to adolescents ages 12 to 17. It was the first FDA approval of a drug for migraine prevention in this age group.… Read More
MONTREAL — The Food and Drug Administration has approved Impavido, for the tropical disease leishmaniasis, which has plagued U.S. troops deployed to areas such as Iraq. Leishmaniasis is caused by Leishmania, a parasite which is transmitted to humans through sand… Read More
SUMMIT, NJ — Clinicians have a new tool in their arsenal to treat active psoriatic arthritis. The Food and Drug Administration recently approved Otezla (apremilast) to treat adults with active psoriatic arthritis (PsA). The drug is marketed by Celgene Corporation,… Read More
Highest Customer Satisfaction for Fourth Year in A Row By Annette M. Boyle MILWAUKEE — For the fourth year in a row, the VA’s Consolidated Mail Outpatient Pharmacy (CMOP) received the highest customer satisfaction score among the nation’s public and… Read More
WASHINGTON — For the first time, the Food and Drug Administration is allowing marketing of a device as a preventive treatment for migraine headaches. The transcutaneous electrical nerve stimulation (TENS) device, marketed as Cefaly, also is the first to be… Read More
PHILADELPHIA — A new nonsteroidal anti-inflammatory drug (NSAID) was recently approved by the Food and Drug Administration for the treatment of mild to moderate pain in adults. Iroko Pharmaceuticals, LLC, announced that its product Tivorbex was approved in 20 mg… Read More
WASHINGTON — Label changes on Doribax (doripenem), an antibacterial drug used to treat ventilator-associated pneumonia, have been approved by the Food and Drug Administration. The FDA said the drug carries an increased risk of death and lower clinical cure rates… Read More
By Annette M. Boyle WASHINGTON — Originally launched in March 2003 and restarted in October 2009, the Pharmacy Reengineering (PRE) software development project continues to miss deadlines, stumble in deployment and suffer from project management failures. That’s according to a… Read More
BEDFORD, MA — The first gel sealant has been approved to stop leaking fluid through the corneal incision after cataract surgery with intraocular lens placement. Until the Food and Drug Administration approved the ReSure Sealant Kit, stitches were the only… Read More
PHILADELPHIA — Accelerated approval has been granted by the Food and Drug Administration to a combination therapy for unresectable or metastatic melanoma with a specific mutation. Approval was announced of a trametinib-dabrafenib combination for use in the treatment of patients… Read More
WASHINGTON — With a second study showing increased risk of cardiovascular events among men using testosterone replacement therapy, the Food and Drug Administration announced that it is reassessing the safety of those products. The agency said it is investigating the… Read More
SAN DIEGO — The Food and Drug Administration has approved a new opioid analgesic but not without controversy. In approving Zohydro ER (hydrocodone bitartrate extended-release capsules), the FDA went against an 11-2 recommendation by a panel of outside experts to… Read More
SUNNYVALE, CA — For the first time, the Food and Drug Administration is allowing marketing of a device to relieve pain caused by migraine headaches that are preceded by an aura. The device, the Cerena Transcranial Magnetic Stimulator (TMS), is… Read More
WASHINGTON — A new sodium-glucose co-transporter 2 (SGLT2) inhibitor has been approved to treat type 2 diabetes. The Food and Drug Administration approved Farxiga (dapaglifozin) tablets to improve glycemic control, along with diet and exercise, in adults. Farxiga is marketed… Read More
WASHINGTON — Use of novel anticoagulants has risen sharply both at the VA and in the Army in the last three years, freeing more atrial fibrillation patients from food restrictions and regular checks for coagulation time, as required when using warfarin.
DENVER — Personalized attention from a pharmacist increases medication adherence in patients to nearly 90% in the year following hospitalization for acute coronary syndrome (ACS), according to a recent study.